Cancer stem cells as a potential therapeutic target in thyroid carcinoma (Review)

Luisa Vicari, Cristina Colarossi, Dario Giuffrida, Ruggero De Maria, Lorenzo Memeo

Research output: Contribution to journalReview article

Abstract

A number of studies have indicated that tumor growth and proliferation is dependent on a small subset of cells, defined as cancer stem cells (CSCs). CSCs have the capability to self-renew, and are involved with cancer propagation, relapse and metastatic dissemination. CSCs have been isolated from numerous tissues, including normal and cancerous thyroid tissue. A regulatory network of signaling pathways and microRNAs (miRNAs) control the properties of CSCs. Differentiated thyroid carcinoma is the most common type of endocrine cancer, with an increasing incidence. Anaplastic thyroid carcinoma is the most rare type of endocrine cancer; however, it also exhibits the highest mortality rate among thyroid malignancies, with an extremely short survival time. Thyroid CSCs are invasive and highly resistant to conventional therapies, including radiotherapy and chemotherapy, which results in disease relapse even when the primary lesion has been eradicated. Therefore, targeting thyroid CSCs may represent an effective treatment strategy against aggressive neoplasms, including recurrent and radioresistant tumors. The present review summarizes the current literature regarding thyroid CSCs and discusses therapeutic strategies that target these cells, with a focus on the function of self-renewal pathways and miRNAs. Elucidation of the mechanisms that regulate CSC growth and survival may improve novel therapeutic approaches for treatment-resistant thyroid cancers.

Original languageEnglish
Pages (from-to)2254-2260
Number of pages7
JournalOncology Letters
Volume12
Issue number4
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Neoplastic Stem Cells
Thyroid Neoplasms
Endocrine Gland Neoplasms
Therapeutics
Neoplasms
MicroRNAs
Thyroid Gland
Recurrence
Growth
Cell Survival
Radiotherapy
Drug Therapy
Mortality
Incidence

Keywords

  • Effective strategies
  • Thyroid cancer stem cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cancer stem cells as a potential therapeutic target in thyroid carcinoma (Review). / Vicari, Luisa; Colarossi, Cristina; Giuffrida, Dario; De Maria, Ruggero; Memeo, Lorenzo.

In: Oncology Letters, Vol. 12, No. 4, 01.10.2016, p. 2254-2260.

Research output: Contribution to journalReview article

Vicari, Luisa ; Colarossi, Cristina ; Giuffrida, Dario ; De Maria, Ruggero ; Memeo, Lorenzo. / Cancer stem cells as a potential therapeutic target in thyroid carcinoma (Review). In: Oncology Letters. 2016 ; Vol. 12, No. 4. pp. 2254-2260.
@article{f3975b0a4b4444d1a5acba6d5fc1954e,
title = "Cancer stem cells as a potential therapeutic target in thyroid carcinoma (Review)",
abstract = "A number of studies have indicated that tumor growth and proliferation is dependent on a small subset of cells, defined as cancer stem cells (CSCs). CSCs have the capability to self-renew, and are involved with cancer propagation, relapse and metastatic dissemination. CSCs have been isolated from numerous tissues, including normal and cancerous thyroid tissue. A regulatory network of signaling pathways and microRNAs (miRNAs) control the properties of CSCs. Differentiated thyroid carcinoma is the most common type of endocrine cancer, with an increasing incidence. Anaplastic thyroid carcinoma is the most rare type of endocrine cancer; however, it also exhibits the highest mortality rate among thyroid malignancies, with an extremely short survival time. Thyroid CSCs are invasive and highly resistant to conventional therapies, including radiotherapy and chemotherapy, which results in disease relapse even when the primary lesion has been eradicated. Therefore, targeting thyroid CSCs may represent an effective treatment strategy against aggressive neoplasms, including recurrent and radioresistant tumors. The present review summarizes the current literature regarding thyroid CSCs and discusses therapeutic strategies that target these cells, with a focus on the function of self-renewal pathways and miRNAs. Elucidation of the mechanisms that regulate CSC growth and survival may improve novel therapeutic approaches for treatment-resistant thyroid cancers.",
keywords = "Effective strategies, Thyroid cancer stem cells",
author = "Luisa Vicari and Cristina Colarossi and Dario Giuffrida and {De Maria}, Ruggero and Lorenzo Memeo",
year = "2016",
month = "10",
day = "1",
doi = "10.3892/ol.2016.4936",
language = "English",
volume = "12",
pages = "2254--2260",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Cancer stem cells as a potential therapeutic target in thyroid carcinoma (Review)

AU - Vicari, Luisa

AU - Colarossi, Cristina

AU - Giuffrida, Dario

AU - De Maria, Ruggero

AU - Memeo, Lorenzo

PY - 2016/10/1

Y1 - 2016/10/1

N2 - A number of studies have indicated that tumor growth and proliferation is dependent on a small subset of cells, defined as cancer stem cells (CSCs). CSCs have the capability to self-renew, and are involved with cancer propagation, relapse and metastatic dissemination. CSCs have been isolated from numerous tissues, including normal and cancerous thyroid tissue. A regulatory network of signaling pathways and microRNAs (miRNAs) control the properties of CSCs. Differentiated thyroid carcinoma is the most common type of endocrine cancer, with an increasing incidence. Anaplastic thyroid carcinoma is the most rare type of endocrine cancer; however, it also exhibits the highest mortality rate among thyroid malignancies, with an extremely short survival time. Thyroid CSCs are invasive and highly resistant to conventional therapies, including radiotherapy and chemotherapy, which results in disease relapse even when the primary lesion has been eradicated. Therefore, targeting thyroid CSCs may represent an effective treatment strategy against aggressive neoplasms, including recurrent and radioresistant tumors. The present review summarizes the current literature regarding thyroid CSCs and discusses therapeutic strategies that target these cells, with a focus on the function of self-renewal pathways and miRNAs. Elucidation of the mechanisms that regulate CSC growth and survival may improve novel therapeutic approaches for treatment-resistant thyroid cancers.

AB - A number of studies have indicated that tumor growth and proliferation is dependent on a small subset of cells, defined as cancer stem cells (CSCs). CSCs have the capability to self-renew, and are involved with cancer propagation, relapse and metastatic dissemination. CSCs have been isolated from numerous tissues, including normal and cancerous thyroid tissue. A regulatory network of signaling pathways and microRNAs (miRNAs) control the properties of CSCs. Differentiated thyroid carcinoma is the most common type of endocrine cancer, with an increasing incidence. Anaplastic thyroid carcinoma is the most rare type of endocrine cancer; however, it also exhibits the highest mortality rate among thyroid malignancies, with an extremely short survival time. Thyroid CSCs are invasive and highly resistant to conventional therapies, including radiotherapy and chemotherapy, which results in disease relapse even when the primary lesion has been eradicated. Therefore, targeting thyroid CSCs may represent an effective treatment strategy against aggressive neoplasms, including recurrent and radioresistant tumors. The present review summarizes the current literature regarding thyroid CSCs and discusses therapeutic strategies that target these cells, with a focus on the function of self-renewal pathways and miRNAs. Elucidation of the mechanisms that regulate CSC growth and survival may improve novel therapeutic approaches for treatment-resistant thyroid cancers.

KW - Effective strategies

KW - Thyroid cancer stem cells

UR - http://www.scopus.com/inward/record.url?scp=84983375517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983375517&partnerID=8YFLogxK

U2 - 10.3892/ol.2016.4936

DO - 10.3892/ol.2016.4936

M3 - Review article

AN - SCOPUS:84983375517

VL - 12

SP - 2254

EP - 2260

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 4

ER -